Noticias de PFE_US
Noticias del mercado
Últimas noticias sobre PFE_US — 665 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.
Eli Lilly is dominating the GLP-1 market with nearly 50% revenue growth and a newly approved oral obesity pill. Pfizer is rebuilding its pipeline with obesity drug ambitions and a committed dividend through its transformation.
Ten consecutive earnings beats and a shrinking COVID hangover have Wall Street split on whether Pfizer deserves a breakout or a ceiling, and the answer hinges on a single pipeline deal that could reshape the obesity drug race.
Las acciones de Pfizer cuestan 24,70 EUR en las operaciones del fin de semana del 4 de octubre de 2026, frente al cierre de Xetra de 24,70 EUR.
Pfizer stock was last at USD 27.80 on October 2, 2026, down 1.14 percent. Q2 revenue reached USD 15.
Pfizer stock carried USD 27.80 into October after Q2 adjusted EPS reached USD 0.77 against USD 0.68
Pfizer (PFE) Quietly Builds New Cancer And RSV Powerhouse
Florida Attorney General James Uthmeier filed a lawsuit Thursday against Pfizer Inc., alleging unfair and deceptive marketing of Pfizer’s COVID-19 vaccine.
Pfizer Sues Sun Pharmaceutical to Block Copies of Cancer Drug
Novo Nordisk boasts a 33% net margin and fortress balance sheet, while Pfizer trades cheaper but faces major patent cliffs through 2030.
Página 19 de 34